This stock is no longer traded. It was delisted on July 14, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which serve patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional LDL-C lowering. These therapies address patients who are statin-intolerant or require supplementary cholesterol management beyond traditional treatments. Esperion has expanded its global reach through partnerships, with its bempedoic acid products now available in markets including Japan and Canada. The company operates in the cardiovascular health segment, focusing on closing treatment gaps in dyslipidemia management. Founded in 1998 and headquartered in Ann Arbor, Michigan, Esperion operates as a commercial-stage biopharmaceutical company dedicated to advancing treatment options for patients with elevated cholesterol and related cardiovascular risk factors.
Website3891 Ranchero Drive
Ann Arbor, MI, 48108
United States
The latest articles about ESPR.
Summary of Oct 21's posts. Generated by AI.
Summary of May 4's posts. Generated by AI.
Summary of May 5's posts. Generated by AI.
Summary of May 2's posts. Generated by AI.
Investors talking about ESPR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.